Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
CCG 1423 (HB3389)
Description:Rho/SRF pathway inhibitor. Induces intermediate mesoderm differentiation from ESCs.
Purity:>99%
Pertussis Toxin (HB4729)
Description:Catalyzes ADP-ribosylation of the G proteins Gαi, Gαo and Gαt
Purity:>98%
YM-254890 (HB6283)
Description:Potent Gq/11 signaling inhibitor. Reported as Gq- G-protein inhibitor and broad-spectrum inhibitor for Gq- and Gs-proteins.
Purity:>98%
Zoledronic acid (HB0674)
Description:Highly potent bisphosphonate, shows variety of biological actions